Halozyme Therapeutics HALO Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $136.42M+17.8% | $115.85M-2.1% | $118.37M-49.6% | $234.7M+96.9% | ||
| $426.27M+47.9% | $288.2M+23.6% | $233.25M+0.1% | $232.99M+153% | ||
| $20.77M-62.4% | $55.27M— | $0-100% | $100.12M+85.7% | ||
| $825.21M-24.0% | $1.09B+45.4% | $746.42M+1.0% | $739.01M-20.2% | ||
| $44.44M+8.8% | $40.86M+7.2% | $38.11M+8.6% | $35.1M+417% | ||
| $580.36M+39.2% | $416.82M0.0% | $416.82M+1.9% | $409.05M— | ||
| $981.47M+144% | $401.83M-15.0% | $472.88M-13.5% | $546.65M— | ||
| $2.53B+22.4% | $2.06B+19.1% | $1.73B-5.9% | $1.84B+66.7% | ||
| $20.9M+104% | $10.25M-13.3% | $11.82M-33.2% | $17.69M+1,048% | ||
| —— | —— | —— | $5.5M+28.6% | ||
| $0— | $0— | $0-100% | $13.33M-85.1% | ||
| $177.09M+27.3% | $139.1M+23.7% | $112.49M-14.0% | $130.79M+11.6% | ||
| $2.14B+42.3% | $1.51B+0.4% | $1.5B+0.4% | $1.49B+89.6% | ||
| $2.48B+45.7% | $1.7B+3.0% | $1.65B-1.3% | $1.67B— | ||
| 300M+243,802% | 123K-3.1% | 127K-5.9% | 135K-2.2% | ||
| $54.79M-84.8% | $359.87M+297% | $90.55M-36.8% | $143.22M+343% | ||
| $48.81M-86.6% | $363.82M+334% | $83.81M-50.6% | $169.8M-13.8% | ||
| $2.53B+22.4% | $2.06B+19.1% | $1.73B-5.9% | $1.84B+66.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Halozyme Therapeutics's total assets?
- Halozyme Therapeutics (HALO) holds $2.7B in total assets, up 21.7% year over year.
- How much debt does Halozyme Therapeutics have?
- Halozyme Therapeutics carries $2.2B in total debt against $219.6M of shareholders' equity, a debt-to-equity ratio of 9.91.
- How much cash does Halozyme Therapeutics have?
- Halozyme Therapeutics holds $312.0M in cash and equivalents.
- Can Halozyme Therapeutics cover its short-term obligations?
- Its current ratio is 2.76 — current assets exceed current liabilities.
- Where does Halozyme Therapeutics's balance sheet data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
